SecBot SecBot
8-K ·Filed Apr 30, 2026

HALO

HALOZYME THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001159036-26-000053
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading catalyst. Monitor the next quarterly earnings call for any strategic or capital allocation shifts under the new CFO. The appointment of a seasoned J&J finance executive is incrementally positive for governance credibility but does not change near-term fundamentals.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$63.66
T+0 close · Apr 30, 2026 · via day close
Latest settled
+27.99%
T+60 · $81.48
Vs SPY
+24.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $63.66entry
  2. T+1 · 7mo ago +0.47%α +0.25% · $63.96
  3. T+5 · 6mo ago +4.23%α +2.50% · $66.35
  4. T+20 · 6mo ago +7.10%α +2.13% · $68.18
  5. T+60 · 4mo ago +27.99%α +24.88% · $81.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Halozyme appointed Darren Snellgrove as permanent CFO, effective June 8, 2026, replacing interim CFO David Ramsay who will stay on in an advisory role. Snellgrove brings deep biopharma finance experience from 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector. This is a routine executive appointment with no material financial impact.

Key Facts

  • Darren Snellgrove appointed CFO effective June 8, 2026, replacing interim CFO David Ramsay
  • Snellgrove spent 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector
  • Annual base salary of $670,000 with 50% bonus target, new-hire equity awards totaling $7,200,000 ($3.2M RSUs + $4.0M stock options), and a $350,000 sign-on cash bonus
  • Current interim CFO David Ramsay will remain in an advisory role during the transition

Financial Impact

New CFO compensation package includes $670,000 salary, $7.2M equity grant, and $350,000 sign-on bonus, immaterial relative to $7.5B market cap

Risk Factors

  • Transition risk if Snellgrove's strategic priorities diverge from the interim CFO's approach
  • No change to underlying business fundamentals or revenue outlook

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
73% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001159036-26-000053
Document: darrensnellgrovepressrelea.htm0001159036-26-000053
Document: 0001159036-26-000053-index-headers.html0001159036-26-000053
Document: 0001159036-26-000053-index.html0001159036-26-000053
Document: 0001159036-26-000053.txt0001159036-26-000053

Track record

15 reports on HALO

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
  2. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  4. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
  5. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
  6. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  7. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  8. Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  9. Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  10. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026